DIACCURATE
8.7.2021 08:02:16 CEST | Business Wire | Press release
DIACCURATE, a French biotechnology company that develops sole-in-class therapeutics in immunotherapy, oncology and infectiology today announced the formation of its Scientific Advisory Board (SAB). Composed of 6 independent world-leading experts in the fields of basic and translational immunology, lipid metabolism, oncology and immunotherapy DIACCURATE’s SAB is chaired by Professor Tasuku HONJO, Kyoto University’s Institute for Advanced Study (KUIAS), awarded by the 2018 NOBEL PRIZE in Physiology or Medicine for his discovery of "immune checkpoint inhibitors", a key step in the history of cancerology.
Dr. Dominique BRIDON, CEO of DIACCURATE , commented: "We feel honored to have gathered this world-renowned group of experts in our newly formed Scientific Advisory Board around Prof. Jacques THÈZE, CSO and Scientific co-Founder of DIACCURATE”. He added: “We look forward to building on their exceptional knowledge and complementary experience in immunology, immunotherapy and oncology to progress our highly original and ambitious pipeline towards the clinic.”
“Cancer treatment has seen a revolution in immunotherapy. Extensive research to which my lab has contributed has brought to light the importance of cytotoxic CD8 T cells in the antitumor immune response, giving rise to current immune checkpoint inhibitors. But the role of CD4 T cells in this response had so far remained overlooked”, said Prof. Tasuku HONJO, Deputy Director-General of KUIAS and Chairman of DIACCURATE’s SAB . He explained: “Recent findings have demonstrated the key contribution of CD4 T cells to clinical efficacy of PD-L1/PD-1 blockade therapies.The developments undertaken at DIACCURATE to boost CD4 T cells functionality could represent a major step towards improving immunotherapy.”
Prof. Christoph HUBER, co-founder of the mRNA vaccine pioneer BioNTech, board member of the International Association of Cancer Immunotherapy and member of DIACCURATE’s SAB , added: “As we have seen once again with the COVID-19 pandemic, vaccines are an unvaluable immunotherapy tool to prevent and treat diseases that affect the immune system. It has been well known for over a century in the field of infectious diseases, it is also becoming an evidence in the field of oncology, and strategies like that of DIACCURATE that potentiate CD4 T cells response are expected to further improve the efficacy and the profile of vaccines”.
Dr. Bernard MALISSEN, Founder and Director of the Center for Immunophenomics, team leader and former Director of the Centre d'Immunologie de Marseille Luminy and member of DIACCURATE’s SAB , concluded: “Intricate biological networks control physiological and pathologic processes and revolve around biological switches. By integrating incoming signals and determining the downstream pathways that need to be activated, they constitute key “decision makers”. DIACCURATE has laid solid foundations to take on the challenge of targeting such biological switches, which are of tremendous importance in various pathological contexts, including cancer and infectious diseases”.
DIACCURATE
DIACCURATE is a late preclinical stage biotechnology company that invests the new frontiers of immunotherapy and oncology, firstly CD4 immunotherapy and targeted chemotherapy. At the forefront of translational medicine, these sole-in-class drug candidates target incurable diseases: refractory acute myeloid leukemia, pancreatic cancer and AIDS. DIACCURATE is conducting 3 proprietary development programs and expects to start its first clinical trial by 2022.
DIACCURATE is supported by a high-level management team led by Dr. Dominique BRIDON and world-class Board of Directors and Scientific Advisory Board chaired by Dr. Philippe POULETTY, CEO of TRUFFLE, and Prof. Tasuku HONJO, 2018 Nobel Prize in Medicine.
For more information, visit www.diaccurate.com and follow @DiaccurateTx
TRUFFLE CAPITAL
Created in 2001, TRUFFLE CAPITAL is an independent European Venture Capital company, specialising in life sciences (MedTech and Biotech) and in breakthrough IT technologies (FinTech and InsurTech). The mission of TRUFFLE CAPITAL is to help the creation and development of young innovating companies, capable of becoming tomorrow’s leaders.
Chaired by Patrick KRON and led by Dr. Philippe POULETTY et Bernard-Louis ROQUES, co-founders and CEOs, TRUFFLE CAPITAL has raised over €1.1 billion since its inception and helped over 70 companies in the digital technology and life sciences sectors. In 2019, TRUFFLE CAPITAL announced having raised almost €400 million in new institutional funds, including €250 million for new BioMedTech investments.
For more information, visit www.truffle.com and follow @trufflecapital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005604/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Announces Appointment of New Chief Financial Officer16.2.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization. “Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition
REJO brings CUBE modular device to Japan in its global premiere16.2.2026 03:00:00 CET | Press release
FlexiCUBE™, the world’s first modular heat-not-burn device, offers adult users customizable color combinations OmniHeat™ 360° technology elevates consistent aerosol performance to new levels Puff Twice feature enables a second heating cycle for auto-heat HNB sticks, allowing adult users access more value from every stick REJO, a pioneering global provider of heat-not-burn (HNB) solutions, today announced the global debut of REJO CUBE, its latest modular HNB device, in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215596376/en/ REJO CUBE DEVICE-Product Infographic Breaking away from conventional HNB design norms, REJO CUBE introduces a bold new device option featuring a trendy design and dual-mode inhalation experience, launching on Japan’s major e-commerce retail channels from February 16. This launch marks the brand’s latest move following REJO Mate Air’s introduction in Japan in July 2025, when the device’s comp
Sultan bin Ahmed Visits Shanghai Film Studios, Film Park and Stadium15.2.2026 20:24:00 CET | Press release
His Highness Sheikh Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, visited the 800,000-square-metre Shanghai Film Studios and Film Park in the town of Shidon in the Chinese city of Shanghai on Saturday. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215440594/en/ Sultan bin Ahmed visits Shanghai Film Studios, Film Park and Stadium (Photo: AETOSWire) His Highness watched a video outlining the specifications of the Shanghai studios, which comprise 4 professional studios ranging in size from 800 to 3000 square metres, a large costume warehouse, production support facilities, classic cars, and an integrated set of production services. His Highness was briefed on the work produced using artificial intelligence technologies. He toured the sound recording rooms, image quality control, editing and post-production facilities, and listened to an explanation on the developme
Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management15.2.2026 18:45:00 CET | Press release
Estithmar Holding Q.P.S.C. announced today the establishment of its fifth group, “Estithmar Capital,” in a strategic step aimed at strengthening the company’s expansion and diversifying the sectors in which it operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215458570/en/ Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management (Photo: AETOSWire) Estithmar Capital will specialize in managing financial investments, strengthening institutional governance, and operating under clear frameworks for compliance, regulation, and risk management, reflecting Estithmar Holding’s vision for sustainability and responsible, well-structured growth. The establishment of Estithmar Capital supports Estithmar Holding’s broader strategy of diversifying financial assets, improving capital efficiency, and unifying governance practices across various markets. Through a centralized and disciplined approach, t
Align Partners Issues Third Public Shareholder Letter and Submits Formal Shareholder Proposals to Coway14.2.2026 12:31:00 CET | Press release
Align Partners highlights Coway’s persistent undervaluation despite steady global growth, citing structural ROE decline as a key driver Align Partners urges the Board to address inefficient capital structure and strengthen shareholder return discipline; requests a formal response by March 13, 2026 The proposals call for stronger Board independence, enhanced Audit Committee oversight, and improved compensation transparency Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway” or the “Company”), has submitted formal shareholder proposals for the Company’s upcoming 37th Annual General Meeting (“AGM”) and issued its third public shareholder letter to Coway’s Board of Directors. Coway is South Korea’s leading home appliance rental platform, supported by a strong global brand and sales network. Since Netmarble became the largest shareholder in 2020, Coway has delivered steady operating growth, with revenue and operating profit increasing at comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom